Sponsored Links
| MabThera Approved In The EU For Patients With Chronic Lymphocytic Leukaemia |
 |
 |
 |
| Medical News - Lymphology and Lymphedema | |||
|
Roche announced that the European Commission has approved MabThera (rituximab) in combination with chemotherapy for use in patients with previously-untreated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia to affect adults. The approval is based on compelling results from the pivotal phase III study CLL8. Read more: Lymphology/Lymphedema News From Medical News Today
|